组合治疗对2型糖尿病中脏内皮功能的影响
Merve Günes-Altan1,2, Agnes Bosch1, Kristina Striepe1
1Department of Nephrology and Hypertension, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Kidney international reports
|October 27, 2025
概括
氧化 (NO) 活性影响2型糖尿病 (T2DM) 患者的动力学,这些患者接受了empagliflozin和linagliptin (E+L) 治疗. 这种NO活性是脏对E+L治疗的血液动力学反应的关键因素.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 与脏血液动力学的改变有关.
- 之前的研究表明,使用empagliflozin和linagliptin (E+L) 联合治疗会影响T2DM患者的脏血液动力学.
研究的目的:
- 调查氧化 (NO) 在血管中的活性对T2DM患者E+L组合疗法诱导的血液动力学变化的作用.
主要方法:
- 在T2DM患者中,随机对照试验比较E+L与甲福林和胰岛素格拉金 (M+I) 3个月.
- 通过清除技术评估的脏血液动力学 (脏血流量,膜过率).
- 通过测量脏血流量的变化来评估脏NO活性,以应对NO抑制剂 (L-NMMA).
主要成果:
- 治疗E+L与脏血流量 (RPF),脏血管抵抗 (RVR) 和与NO活性相关的异动动脉抵抗 (RE) 的变化有显著的相关性.
- 在M + I组中,没有观察到脏NO活性和血液动力学变化之间的显著相关性.
- 在这两组中都没有检测到脏NO活性的整体变化.
结论:
- 脏NO活性是T2DM中对E+L组合疗法的脏血液动力学反应的决定因素.
- 像empagliflozin这样的-葡萄糖共运输体-2 (SGLT-2) 抑制剂的治疗效果可能部分通过影响脏NO活性来调解.
相关概念视频
01:15Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
01:22Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
01:30Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209